Document is current
Any future updates will be listed below
-
Authors
Stegenborg, Fie https://orcid.org/0009-0006-9591-4500
Bidstrup, Pernille Envold https://orcid.org/0000-0002-9704-6800
Rostgaard, Klaus https://orcid.org/0000-0001-6220-9414
Davidsson, Òlafur Birgir
Niemann, Carsten Utoft https://orcid.org/0000-0001-9880-5242
Gögenur, Ismail
Jakobsen, Erik
Dalton, Susanne Oksbjerg
Hjalgrim, Henrik https://orcid.org/0000-0002-4436-6798
- License Information
-
More Information
Article History
Received: 13 August 2025
Revised: 26 February 2026
Accepted: 24 March 2026
First Online: 27 April 2026
Competing interests
: CN reports having received grants from AbbVie, JnJ, Genmab, Octapharma, AstraZeneca, Novo Nordisk Foundation, Danish Cancer Society, EU, and Alfred Benzon foundation outside of the current study, and consulting fees from AbbVie, Janssen, Octapharma, AstraZeneca, CSL Behring, Genmab, Takeda, Beigene, Eli Lilly, MSD, Synamics, and Galapagos not relevant for this study; HH reports having received grants for research projects unrelated to this study, and honoraria for course activity from Danish National Board of Health not relevant for this study. FS, PB, KR, ÒD, IG, EJ and SD declare no competing interests.
: In agreement with the General Data Protection Regulation, the study is registered in the Danish Cancer Institute’s internal register database (journal number: 2021-DCRC-0033). All data used for analyses was pseudo anonymised. According to Danish legislation, studies based solely on Danish national registry data do not require ethical review. All methods were conducted in accordance with the principles of the Declaration of Helsinki.
